Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Regulus; Alnylam; Tekmira; and More

Premium

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs

Patent Number: 8,133,876

Filed: Dec. 30, 2008

Lead Inventor: Frank Bennett, Regulus Therapeutics

The invention, the patent's abstract states, comprises “compounds, compositions, and methods ... for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs, as well as downstream targets of these RNAs, and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.”


Title: Lipids and Compositions for the Delivery of Therapeutics

Application Number: 20120058144

Filed: Nov. 10, 2009

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, “provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.”


Title: Lipid-Encapsulated Interfering RNA

Application Number: 20120058188

Filed: June 24, 2011

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention provides “compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell,” the patent application's abstract states.


Title: Adenoviral VA1 Pol III Expression System for RNAi Expression

Application Number: 20120058522

Filed: Aug. 25, 2011

Lead Inventor: John Rossi, City of Hope

The invention, the patent application's abstract states, comprises “an adenoviral VA1 Pol III expression system for RNAi expression.”


Title: RNAi-Expression Constructs

Application Number: 20120058555

Filed: Nov. 10, 2011

Lead Inventor: Petrus Roelvink, Benitec Biopharma

The invention, the patent application's abstract states, “provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases or disorders.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-10a

Application Number: 20120058915

Filed: Nov. 15, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-203

Application Number: 20120058914

Filed: Nov. 15, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-16b

Application Number: 20120058913

Filed: Nov. 14, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using let-7g

Application Number: 20120058912

Filed: Nov. 14, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-181b

Application Number: 20120058911

Filed: Nov. 14, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Acute Lymphomic Leukemia Using miR-125b

Application Number: 20120058910

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”


Title: Inhibition of MAP4K4 Through RNAi

Application Number: 20120059046

Filed: Nov. 19, 2009

Lead Inventor: Tod Woolf, RXi Pharmaceuticals

The patent application, its abstract states, claims “RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities. … The blunt-ended constructs have a double-stranded region of 19 [to] 49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity.”


Title: Differentiation Therapy for Sarcomas

Application Number: 20120059159

Filed: May 25, 2009

Lead Inventor: Carola Ponzetto, University of Torino Medical School

The invention, the patent application's abstract states, comprises the “use of muscle-enriched/specific microRNAs for the treatment of sarcomas, as for example rhabdomyosarcomas, synovial sarcoma, alveolar soft part sarcoma, liposarcoma, and osteosarcoma, wherein the microRNAs are able to stop the development of neoplastic cells and to force the neoplastic cells to differentiate into terminally differentiated muscle cells.”

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.